A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors
NCT02590952
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
108
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumor
Interventions
DRUG:
Epitinib
Sponsor
Hutchison Medipharma Limited